Health TrialsbyHealthPanel

The Effect of Nanofat Injection on Androgenetic Alopecia

ConditionsAndrogenetic AlopeciaAndrogenetic Alopecia (AGA)
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-50
SponsorAssiut University

About this trial

Androgenetic alopecia is a condition that bothers a lot of people. The disadvantage of the FDA approved topical minoxidil is that the patient needs to be compliant every day for extended periods of time. This is the main reason why this study is being conducted, to see if a single nanofat injection is superior to applying either topical Minoxidil or PRP

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults (ages 18-50).

A clinical diagnosis of androgenetic alopecia confirmed by dermoscopy of both males and females.

No previous topical treatment used in the past 3 months.

Disqualifiers

Alopecia totalis and alopecia universalis.

Cicatricial alopecia.

Other causes of hair loss such as immunological disease.

Skin disease in the affected area.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Minoxidil 5 %

    Drug

    Topical application of minoxidil 5%

  • PRP injection

    Procedure/Surgery

    3 PRP injections one month apart

  • Nanofat injection

    Procedure/Surgery

    Single nanofat injection

Treatment groups

60 Participants
are divided into 3 treatment groups
Group A: Topical minoxidil 5/Active comparator 1 intervention
Group B: PRP injectionActive comparator 1 intervention
Group C: nanofat injectionExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Clinical improvement by using trichoscopy and photographs

Photographs using Hamilton norwood scale for males and Ludwig Scale for females

Time frame
All patients will be evaluated at Day 1 and at 6, 12 and 16 weeks.
2

Trichoscopic improvement

Including hair diameter diversity

Time frame
All patients will be evaluated at Day 1 and at 6, 12 and 16 weeks.
3

patient satisfaction score

It will be used for objective evaluation: * 0 to 25% change = not satisfied, * 26 to 50% = mildly satisfied, * 51 to 75% = moderately satisfied, * 76 to 100% = very satisfied.

Time frame
All patients will be evaluated at Day 1 and at 6, 12 and 16 weeks.

Secondary outcomes

1

Temporal Hairline Position

measuring the distance (in mm) from the lateral canthus to the most anterior terminal hair to track hairline "advancement."

Time frame
All patients will be evaluated at Day 1 and at 6, 12 and 16 weeks.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: